Mindful Innovation Bringing Hope to Patients

Developing new treatments to improve the lives of patients and families affected by epilepsy and neuropsychiatric disorders.

Our Pledge to Patients

Marinus Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings.

Our Science & Pipeline

Postpartum Depression

Striving to Support Strong Mother-Baby Bonds

Developing therapies with the potential to address postpartum depression more quickly and in an outpatient setting.

Learn More

Orphan Epilepsies

Aspiring to Give Children Seizure-Free Days

Ganaxolone offers the potential to safely decrease seizure frequency in children with refractory epilepsy.

Learn More

Why We Work

To make a difference in the lives of patients and their families.

  • Violet

    “She spends time at the park and beach, works hard in school, loves playing with her little brother, and making new friends.”

  • Artwork by G

    “Meet our special little guy who enjoys creating beautiful pieces of art with his mommy to help raise awareness for CDKL5.”

  • Sloan

    “Sloan surprises us with new skills every day and is the sweetest, funniest, spunkiest little girl our family could have been blessed to have.”

  • Artwork by Ava

    This artwork was made by young Ava.

  • Kiera

    “She is a vibrant and intelligent young lady who has a wonderful sense of humor, love for music, dancing, and the moon and stars.”

  • Amanda

    “We call our daughter Amazing Amanda, and quite simply… she IS. Her strength and tenacity wows me; she is my hero!”

Follow Us on Twitter

We just wrapped up an incredible few days with the @AmEpilepsySoc community. #AES2018 was the perfect opportunity to present our recent findings, connect with others also working towards a world without epilepsy, and so much more. The future is bright. Thank you, AES!

Our Phase 2 clinical trial of #ganaxolone shows promise for patients with #CDKL5 & #PCDH19, conditions where existing treatments have shown limited efficacy. Our hope with this research is to advance the understanding and treatment of pediatric epilepsy: https://t.co/3cnMNJHrfp

We stopped by @PCDH19Alliance's booth at #AES2018 and are proud to support their mission.

Sign Up For Updates

Receive periodic updates on program progress, clinical trials, and other timely information.